Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease - Trial NCT06342609
Access comprehensive clinical trial information for NCT06342609 through Pure Global AI's free database. This Phase 4 trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center and is currently Recruitment Completed. The study focuses on Coronary Artery Disease. Target enrollment is 84 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Timeline & Enrollment
Phase 4
Mar 15, 2023
Sep 07, 2024
Primary Outcome
Rate of change in low attenuation plaque volume as measured by multidetector computed tomography (MDCT) angiography
Summary
This is a randomized double-blind, placebo-controlled, investigator-initiated trial that
 compares Colchicine 0.5mg/day with placebo, among patients with stable CAD. Subjects will be
 educated to maintain medication compliance with other prescribed medications.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06342609
Non-Device Trial